Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EPS (Basic) (2017 - 2025)

Protagonist Therapeutics' EPS (Basic) history spans 9 years, with the latest figure at -$0.69 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 132.39% year-over-year to -$0.69; the TTM value through Dec 2025 reached -$2.05, down 145.86%, while the annual FY2025 figure was -$2.05, 145.86% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.69 at Protagonist Therapeutics, down from -$0.62 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.41 in Q1 2024 and bottomed at -$0.84 in Q2 2022.
  • The 5-year median for EPS (Basic) is -$0.59 (2023), against an average of -$0.21.
  • The largest annual shift saw EPS (Basic) crashed 233.33% in 2021 before it skyrocketed 608.96% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.77 in 2021, then grew by 9.09% to -$0.7 in 2022, then skyrocketed by 174.29% to $0.52 in 2023, then soared by 309.62% to $2.13 in 2024, then tumbled by 132.39% to -$0.69 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's EPS (Basic) are -$0.69 (Q4 2025), -$0.62 (Q3 2025), and -$0.55 (Q2 2025).